Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03288454 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT
A Phase 2 study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03288454: Completed Phase 2 study, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
NCT03288454 is a Phase 2 study that has completed, run by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03288454, a Phase 2 study, has completed, sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).
Interventions
- DRUG Placebo
- DRUG Apixaban
- DRUG Ciraparantag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-08-30 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 2 |
Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals9 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03288454
The ClinicalTrials.gov registry entry for NCT03288454 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03288454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03288454 about?
NCT03288454 is a clinical study titled "Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT". This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with apixaban measuring clotting times using Whole Blood Clotting Time (WBCT).
What is the current status of trial NCT03288454?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-08-30. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT03288454?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), Ciraparantag (DRUG).
Who is sponsoring clinical trial NCT03288454?
This trial is sponsored by Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.